BMS, bluebird refile FDA approval application for CAR-T therapy in myeloma July 30, 2020 Auto Bot BioPharma, biopharma nl, bluebird bio, Bristol-Myers Squibb, Cambridge, CAR-T, cell therapy, Massachusetts, multiple myeloma, New York 0 The companies’ resubmission of their application Wednesday seeking approval for idecabtagene vicleucel was in line with the timeline they provided in May, when the FDA sent a refuse-to-file letter in response to their initial submission.